3.515EUR+2.33%Mkt Cap: 50.62M EURP/E: —Last update: 2026-05-14
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-1.90
PEG—
P/B-17.52
P/S62.26
EV/EBITDA—
EV/Revenue—
EPS (TTM)-0.22
EPS (Forward)-1.84
Cash Flow & Leverage
FCF Yield—
FCF Margin—
Operating CF-821.60K EUR
CapEx (TTM)257.23K EUR
Net Debt/EBITDA—
Net Debt—
Technical
SMA 503.234 (+8.7%)
SMA 2002.583 (+36.1%)
Beta1.50
S&P 52W Chg24.23%
Avg Vol (30d)94.06K
Avg Vol (10d)60.65K
Technical Indicators
RSI (14)58.4
MACD0.0551
MACD Signal0.0652
MACD Hist.-0.0101
BB Upper3.607 EUR
BB Middle3.417 EUR
BB Lower3.228 EUR
BB Width11.08%
ATR (14)0.1902 EUR
Vol Ratio (20d)1.57x
52W Range
0.742064% of range5.100
52W High5.100 EUR
52W Low0.7420 EUR
Profitability
Gross Margin-191.39%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-41659.08%
ROE-103.45%
ROA-28.46%
Revenue Growth-90.10%
Earnings Growth—
Balance Sheet
Debt/Equity0.99
Current Ratio—
Quick Ratio—
Book Value/Sh-0.2000 EUR
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.14.44M
Float—
Insiders10.79%
Institutions7.78%
Analyst Consensus
Rating—
Target (Mean)5.800 EUR
Target Range5.800 EUR – 5.800 EUR
# Analysts1
Company
Market Cap50.62M EUR
Enterprise Value—
Revenue (TTM)813.00K EUR
Gross Profit-2.34M EUR
Net Income (TTM)-3.00M EUR
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price3.515 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013286259